Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

NCT03761056 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Lymphoma

Interventions

BIOLOGICAL: Axicabtagene Ciloleucel
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Kite, A Gilead Company